Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
Eligibility Criteria
- * Male and female adults ≥ 18 years of age with a life expectancy ≥ 6 months; Karnofsky performance status ≥ 70%; Histologically confirmed Hodgkin lymphoma or Non-Hodgkin lymphoma; Candidate for AHCT consolidation therapy as assessed by their treating physician; Achieved a complete or partial response; Completed collection of at least 2.0 x 10\^6 CD34 cells/kg of autologous hematopoietic progenitor cells (HPCs) by apheresis; Recovery from non-hematologic toxicities of salvage cytoreductive chemotherapy to ≤ grade 2; Clinical laboratory and organ function criteria meeting study ranges/limits LVEF ≥ 50%; FEV1 \> 65% of predicted measurement, DLCO ≥ 50% of predicted; Seronegative for HIV Ag/Ab combo, HCV, active HBV, and syphilis
- * Prior high-dose chemotherapy with autologous stem cell transplant, or prior allogeneic transplantation; Significant prior external beam dose-limiting radiation to a critical organ based on review of the prior radiation treatment records; Use of any other investigational medication or device, or concurrent biological, chemotherapy, or radiation therapy; Myelodysplasia or any active malignancy other than HL or NHL, or \< 5 years remission from any other prior malignancy; Any cytogenetic abnormality in the bone marrow that is known to be associated with or predictive of myelodysplasia; Persistent marrow involvement (\>10%) with HL or NHL after salvage cytoreductive therapy and before stem cell mobilization; Not having sufficient bone marrow harvest to reach adequate cell dose for transplant; Active hepatitis B or C viral infection or HBsAg positive; Positive HIV antibody;
Ages Eligible for Study
18 Years to
Sexes Eligible for Study
ALL
Accepts Healthy Volunteers
No